Movement Alert｜ASCENTAGE Falls 5.09% in Regular Trading, Trading at HK$32.46

Market Focus

Sep 10

On September 10, ASCENTAGE fell 5.09% in regular trading, trading at HK$32.46 per share, with turnover of HK$53.27 million.

Within the Biotechnology sector where ASCENTAGE belongs, the overall sector trended lower. Among individual stocks, INNOVENT BIO down 2.9%, AKESO down 1.0%, 3SBIO down 3.41%, BEONE MEDICINES down 0.67%, EVEREST MED down 7.56%.

ASCENTAGE is an investment holding company principally engaged in the discovery, development and commercialization of therapies for hematological malignancies. Its core products include Nailike (olverembatinib) and lisaftoclax, primarily used in the treatment of chronic myeloid leukemia, acute myeloid leukemia, and various other hematological malignancies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1186659336"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186659336\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186659336?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 13:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186659336","market":"us","top_or_hot":-1,"title":"Movement Alert｜ASCENTAGE Falls 5.09% in Regular Trading, Trading at HK$32.46","media":"Market Focus","content":"<p><p>On September 10, ASCENTAGE fell 5.09% in regular trading, trading at HK$32.46 per share, with turnover of HK$53.27 million.</p><p>Within the Biotechnology sector where ASCENTAGE belongs, the overall sector trended lower. Among individual stocks, INNOVENT BIO down 2.9%, AKESO down 1.0%, 3SBIO down 3.41%, BEONE MEDICINES down 0.67%, EVEREST MED down 7.56%.</p><p>ASCENTAGE is an investment holding company principally engaged in the discovery, development and commercialization of therapies for hematological malignancies. Its core products include Nailike (olverembatinib) and lisaftoclax, primarily used in the treatment of chronic myeloid leukemia, acute myeloid leukemia, and various other hematological malignancies.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ASCENTAGE Falls 5.09% in Regular Trading, Trading at HK$32.46</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ASCENTAGE Falls 5.09% in Regular Trading, Trading at HK$32.46\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-10 13:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 10, ASCENTAGE fell 5.09% in regular trading, trading at HK$32.46 per share, with turnover of HK$53.27 million.</p><p>Within the Biotechnology sector where ASCENTAGE belongs, the overall sector trended lower. Among individual stocks, INNOVENT BIO down 2.9%, AKESO down 1.0%, 3SBIO down 3.41%, BEONE MEDICINES down 0.67%, EVEREST MED down 7.56%.</p><p>ASCENTAGE is an investment holding company principally engaged in the discovery, development and commercialization of therapies for hematological malignancies. Its core products include Nailike (olverembatinib) and lisaftoclax, primarily used in the treatment of chronic myeloid leukemia, acute myeloid leukemia, and various other hematological malignancies.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1186659336","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186659336","pubTimestamp":1789016567,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 10, ASCENTAGE fell 5.09% in regular trading, trading at HK$32.46 per share, with turnover of HK$53.27 million.Within the Biotechnology sector where ASCENTAGE belongs, the overall sector...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"走势警报|亚盛常规交易跌5.09%，报32.46港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"On September 10, ASCENTAGE fell 5.09% in regular trading, trading at HK$32.46 per share, with turnover of HK$53.27 million.Within the Biotechnology sector where ASCENTAGE belongs, the overall sector trended lower. Among individual stocks, INNOVENT BIO down 2.9%, AKESO down 1.0%, 3SBIO down 3.41%, BEONE MEDICINES down 0.67%, EVEREST MED down 7.56%.ASCENTAGE is an investment holding company principally engaged in the discovery, development and commercialization of therapies for hematological malignancies. Its core products include Nailike (olverembatinib) and lisaftoclax, primarily used in the treatment of chronic myeloid leukemia, acute myeloid leukemia, and various other hematological malignancies.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}